Detall

El proper 26 de gener a les 11.30h l'Aula Dolors Aleu i Riera del Campus Clínic acollirà el vuitè dels seminari del Cicle Continuat de Conferències de la Facultat de Medicina i Ciències de la Salut. 

El seminari porta per títol "The non-canonical actions of ketamine on brain opioid receptors: problem or opportunity?”  i estarà a càrrec del Dr. Jordi Bonaventura, Ramón y Cajal Researcher, del Departament de Patologia i Terapèutica Experimental.

Aquest seminari, esta adreçat a tot el PDI de la Facultat de Medicina i Ciències de la Salut i els diferents centres de recerca de Barcelona i no requereixen inscripció prèvia per poder assistir-hi.

A continuació trobareu una breu sinopsi dels temes que abordarà el Dr. Bonaventura durant el seminari:

"(S)-ketamine is an enantiomer of (R,S)-ketamine and an FDA and EMA-approved medication for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior. The ketamine enantiomers are controlled substances and have known abuse potential. Recent findings support the notion that (S)-ketamine is the primary mediator of (R,S)-ketamine’s abuse liability. However, the mechanisms underlying the drug’s abuse liability are unknown.

(S)-ketamine’s canonical pharmacological target is the N-methyl-D-aspartate receptor (NMDAR) and this interaction is credited as the main contributor to (S)- and (R,S)-ketamine’s pharmacological actions and therapeutic efficacy. However, (S)-ketamine binds to and activates mu (MOR) and kappa (KOR) opioid receptors but does not interact with delta opioid receptors. The relatively small difference in selectivity of (S)-ketamine for NMDAR over MOR/KOR, as well as the differences in (S)-ketamine’s mode of action at each target (NMDAR antagonist vs. MOR/KOR agonist) suggest that MOR and KOR can contribute to (S)-ketamine’s in vivo pharmacological actions. Thus, it is possible that MORs are involved in mediating (S)-ketamine’s reinforcing effects and human abuse liability whereas KORs may mediate aversive effects of (S)-ketamine as seen at higher, non-reinforcing exposure. However, the extent to which MORs are involved in such actions and the -potentially beneficial- long-term consequences of (S)-ketamine exposure are unknown."

Us hi esperem!